Combination Treatment Beneficial in Albuminuric CKD
7.4 year gain in event-free survival for 50-year-old patients with combo therapy with ACEi/ARB and SGLT2 inhibitors
7.4 year gain in event-free survival for 50-year-old patients with combo therapy with ACEi/ARB and SGLT2 inhibitors
Compared with annual screening for urinary albumin, personalized screening can reduce time spent with undetected albuminuria, testing frequency
Achieving normal blood pressure in childhood cancer survivors is “extremely important” for preventing CKD, according to investigators.
Estimated glomerular filtration rate is a less reliable predictor of CKD regression, according to investigators.
Understanding clinical characteristics associated with a decline in eGFR can help guide optimal use of SGLT2 inhibitors in clinical practice, according to investigators.
Even women meeting objective criteria for CKD and nephrology referral were disadvantaged, according to investigators.
In a Dutch study, each doubling of urine albumin excretion was significantly associated with a 7% increase in overall cancer risk.
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.
Despite similar risk for albuminuria with diabetes, albumin-to-creatinine ratio screening in patients with hypertension remains very low
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.